VERAXA Biotech (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The company, an emerging leader in designing novel cancer therapies, is preparing to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results indicate a potential for increased precision in antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
VERAXA’s proprietary BiTAC approach is designed to improve the accuracy of antibody-based cancer treatments. The company maintains a diversified oncology pipeline of antibody-based formats, including antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and other formats. At the BIO International Convention 2026, VERAXA is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The company’s newsroom provides updates and further information (https://ibn.fm/VRXA).
These forward-looking statements involve risks and uncertainties, as detailed in the company’s filings with the SEC. Undue reliance should not be placed on forward-looking statements, which are based on information available as of the date of this announcement. The company undertakes no duty to update this information unless required by law.
